Targeting Inflammation in Epidermolysis Bullosa: Cytokines, Complications, and Anti-inflammatory Treatments

Conclusions

• The presentation concludes that chronic inflammation is a major driver of morbidity in epidermolysis bullosa and is often as dangerous as infection itself.
• It argues that controlling inflammation can reduce pain, itch, odor, wound burden, scarring, strictures, blindness, and even cancer risk in EB.
• The talk suggests that inflammatory biomarkers such as IL-6, IL-1β, TGF-β, IL-4/13, and IL-17/23 are elevated in at least some EB subtypes and may be useful therapeutic targets.
• A range of repurposed anti-inflammatory drugs, including gentian violet, colchicine, dapsone, thalidomide, losartan, diacerein, dupilumab, and apremilast, show promising but variable benefit.
• Anecdotal and small-study evidence indicates that older treatments like gentian violet and colchicine can meaningfully improve wound size, inflammatory markers, and patient symptoms.
• Among randomized and sponsored trials, Oleogel-S10 stands out as the clearest success, improving wound closure, reducing dressing changes and pain, and decreasing infections in EB.
• The oleogel-S10 data support that anti-inflammatory wound therapy can produce clinically meaningful and durable benefits across EB subtypes, especially in children.
• Losartan appears safe and potentially helpful for fibrosis and scarring in recessive dystrophic EB, but larger trials are still needed to confirm efficacy.
• Diacerein is a plausible IL-1β-targeting therapy for EB simplex, with encouraging early results and ongoing multinational trial validation.
• Overall, the research points to inflammation control as an important complementary strategy to gene- or protein-based EB therapies rather than a replacement for them.